Alzheimer’s Disease | Unmet Need | Agitation in Alzheimer’s Disease | US EU | 2025
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement. Agitation is commonly treated with off-label atypical antipsychotics, in spite of safety warnings they carry related to elevated risk of death in elderly dementia patients. In 2023, Lundbeck / Otsuka’s Rexulti (brexpiprazole) became the first FDA-approved drug to treat agitation associated with AD. Other novel agents are also emerging as potential treatments (e.g., Axsome’s Auvelity). Understanding the drivers of clinical decision-making in agitation and prescriber perceptions of the risk / benefit profiles of today’s approved brand and off-label generic options will help identify opportunities for new product positioning and differentiation in this evolving market.
QUESTIONS ANSWERED
- What are the most important treatment drivers and goals for prescribers in agitation in AD?
- What attributes drive decision-making in agitation in AD, which have limited impact, and which are hidden opportunities?
- How do Rexulti and off-label agents perform on these attributes?
- Based on a conjoint analysis and TPP simulation, what trade-offs across key clinical attributes and price are neurologists willing to make for a hypothetical new drug to treat agitation in AD?
PRODUCT DESCRIPTION
Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers
- Analyze market scenarios for different target product profiles using the TPP Simulator
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in February 2025
Key companies: Otsuka / Lundbeck
Key drugs: Rexulti, quetiapine, risperidone, olanzapine, aripiprazole, citalopram, gabapentin
Key feature
Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
